anti-CD22 CAR T cells

**Anti-CD22 CAR T cells** are an investigational form of chimeric antigen receptor T-cell (CAR-T) therapy, in which a patient's own T lymphocytes are collected, genetically engineered to express a synthetic receptor (CAR) that targets the CD22 antigen on B cells, expanded ex vivo, and reinfused into the patient. The therapy is primarily developed for **relapsed or refractory B-cell malignancies**, including B-cell acute lymphoblastic leukemia (B-ALL) and large B-cell lymphoma, particularly in patients who have failed or relapsed after anti-CD19 CAR T-cell therapy. The engineered T cells specifically recognize and destroy CD22-expressing malignant B cells. CD22 is an alternative surface marker on B cells, allowing this therapy to mitigate relapse due to loss of CD19 expression. Anti-CD22 CAR T cell therapy has shown strong signals of efficacy in early-phase studies, with complete response rates around 68% in B-ALL and 64% in non-Hodgkin's lymphoma, and received FDA Breakthrough Therapy Designation for B-ALL and large B-cell lymphoma to expedite its clinical development. Safety signals include cytokine release syndrome (CRS), neurotoxicity, hematologic toxicities, and occasional hemophagocytic lymphohistiocytosis (HLH)-like symptoms, but overall severe neurotoxicity is less frequent than with CD19 CAR-T[1][2][4][5][7].

Other names

CD22 CAR T cellsCD-22 CAR T cellsCD 22 CAR T cells